


Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P22618		Serial No. 10/631,795	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Kouichi SEKIYA et al.			
				Filing Date August 1, 2003		Group 1624	



U.S. PATENT DOCUMENTS									
EXAMINER INITIAL	DOCUMENT NO.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
MB	5	9 4 8 9 1 3	09/07/99	YAMAMOTO et al.					
MB	5	8 6 1 4 0 4	01/19/99	NIEWÖHMER et al.					
MB	5	7 7 0 6 1 1	06/23/98	BROWN					
MB	5	1 2 4 4 5 5	06/23/92	LOMBARDO					
MB	4	1 9 3 9 2 6	03/18/80	SCHMIECHEN et al.					
MB	4	0 1 2 4 9 5	03/15/77	SCHMIECHEN et al.					
MB	3	9 3 6 4 5 4	02/03/76	SCHWENDER					
MB	3	8 6 2 1 8 9	01/21/75	SCHWENDER					



  

FOREIGN PATENT DOCUMENTS									
DOCUMENT NO.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO			
MB	2	1 6 7 3 5 3	07/20/96	CANADA					
MB	8 -	2 3 1 5 4 5	09/10/96	JAPAN					
MB	0 0	/ 6 8 2 3 1	11/16/00	W.I.P.O.					
MB	9 9	/ 2 4 4 3 2	05/20/99	W.I.P.O.					
MB	1	0 4 3 3 2 4	10/11/00	E.P.O.					
MB	9 6	/ 3 6 6 0 6	11/21/96	W.I.P.O.					
MB	9 6	/ 2 6 9 4 2	09/06/96	W.I.P.O.					
MB	9 6	/ 2 6 2 0 9	08/29/96	W.I.P.O.					
MB	9 5	/ 1 8 8 1 5	07/13/95	W.I.P.O.					
MB	9 5	/ 1 0 5 2 5	04/20/95	W.I.P.O.					
MB	9 5	/ 0 0 5 1 6	01/05/95	W.I.P.O.					
MB	9 4	/ 1 4 7 4 2	07/07/94	W.I.P.O.					
MB	9 4	/ 1 2 4 6 1	06/09/94	W.I.P.O.					
MB	9 4	/ 1 1 0 0 4	05/26/94	W.I.P.O.					
MB	9 3	/ 2 3 4 0 1	11/25/93	W.I.P.O.					
MB	9 2	/ 1 2 9 6 1	08/06/92	W.I.P.O.					

EXAMINER <i>Man Ber</i>	DATE CONSIDERED <i>5/25/04</i>
----------------------------	-----------------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P22618		Serial No. 10/631,795	
				Applicant Kouichi SEKIYA et al.			
				Filing Date August 1, 2003		Group 1624	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		1	First Page of JP 4-253945.				
		2	First Page of JP50-157360.				
		3	First Page of JP 6-504782.				
		4	First Page of JP 9-500376.				
		5	First Page of JP 7-504442.				
		6	First Page of JP 8-501318.				
		6	Angyal, A.M. et al., "Purines as Amplifiers of the Antibiotic Activity of Phleomycin Against <i>Escherichia coli</i> B," J. Gen. Microbiology, (1974), 85, 163-68.				
		8	Beavo, J.A., Multiple Isozymes of Cyclic Nucleotide Phosphodiesterase, Adv. Second Messenger Phosphoprotein Res., 22, 1-38 (1988).				
		9	Beavo, J.A. and Reifsnnyder, D.H., Primary Sequence of Cyclic Nucleotide Phosphodiesterase Isozymes and the design of Selective Inhibitors, Trends Pharm. Sci., 11, 150-155 (1990).				
	1	0	Hidaka, H. and Shibuya, M., A New Assay of Cyclic Nucleotide Phosphodiesterase; its Application to Human Serum, Biochem. Med. 10, 301-311 (1974).				
	1	1	C.D. Nicholson, S.A. Jackman & R. Wilke, The ability of denbufylline cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site, Br. J. Pharmacol, (1989), 97, 889-897.				
	1	2	Torphy, T.J. and Undem, B.J., Phosphodiesterase Inhibitors: New Opportunities for the Treatment of Asthma, Thorax, 46, 512-523 (1991).				
	1	3	Global Initiative for Chronic Obstructive Lung Disease (NIH, National Heart, Lung and Blood Institute) page 6.				
	1	4	Makino et al., International Archives of Allergy and Immunology, 121(Suppliment 1) pages 4, 5, 54, 33, 36-39(2000).				
	1	5	Giembycz, Drugs 59(2), 193 (2000).				
	1	6	Benjamin K. Gill, "Diagram Representing the Roles of Cytokines in Inflammatory Responses" <a href="http://attila.stevens-tech.edu/chembio/bgill/IL_10K.html">http://attila.stevens-tech.edu/chembio/bgill/IL_10K.html</a> .				
EXAMINER					DATE CONSIDERED		
					5/25/04		
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							